Introduction {#Sec1}
============

Sepsis is "a life-threatening condition that arises when the body's response to infection injures its own tissues" \[[@CR1]\]. Despite significant advances in an organized treatment approach to sepsis, it remains the most common cause of death in critically ill patients worldwide \[[@CR2]\] and the most frequent non-cardiac diagnosis in the cardiac intensive care unit \[[@CR3]\]. Sepsis-induced cardiomyopathy (SICM), or sepsis-induced myocardial dysfunction (SIMD), is an increasingly recognized form of transient cardiac dysfunction in the septic patients. Despite implications for patient outcomes, the critical care community has not given significant emphasis on this syndrome and prominent critical care textbooks \[[@CR4], [@CR5]\] do not have dedicated sections on SICM.

While no formal definitions exist for septic cardiomyopathy, most review articles and expert opinions agree on a few fundamental features of this unique form of cardiac dysfunction which are outlined in Fig. [1](#Fig1){ref-type="fig"}. One flaw to note is that in order to meet the criteria of reversibility, the patient must survive the episode. Given the high mortality with sepsis, this leads to bias which may affect both diagnosis and trials in SICM.Fig. 1Proposed diagnostic criteria for sepsis-induced cardiomyopathy

In this review, we will briefly summarize the epidemiology, pathophysiology, and clinical manifestations of SICM and then focus on diagnostic work-up and management in more detail.

Epidemiology {#Sec2}
============

Sepsis-induced cardiomyopathy is encountered in the intensive care unit (ICU), and its prevalence in septic patients ranges from 10 to 70% \[[@CR6]\]. This variety between studies is likely due to a lack of formal diagnostic criteria and under recognition. Moreover, the epidemiologic variance emphasizes the complex factors in sepsis: source and severity, promptness of resuscitation, and different antimicrobial and hemodynamic treatment approaches.

Risk Factors {#Sec3}
------------

A retrospective study of over 200 patients hospitalized with sepsis or septic shock demonstrated a higher prevalence of SICM in patients who were younger, male, those with higher illness severity scores, higher lactate and CRP levels, and pre-existing heart failure \[[@CR7]\]. A more recent Korean study evaluated baseline risk factors for the development of SICM and stress-induced cardiomyopathy compared with controls. Increasing age, diabetes mellitus, pre-existing heart failure, and elevated proBNP were all associated with increased odds ratio for septic cardiomyopathy \[[@CR8]\]. Again, there is some discrepancy between these studies that may be based on patient population (Japanese vs Korean, respectively), but both cite pre-existing heart failure as a risk factor. It should also be noted that in both studies, SICM was defined as an "EF \[ejection fraction\] \< 50% and a ≥ 10% decrease in the patient's baseline LVEF" \[[@CR8]\]. It is possible that patients with RV failure, diastolic dysfunction, and abnormal cardiac strain were missed as will be outlined more later on.

Prognosis {#Sec4}
=========

Interestingly, the initial studies of SICM in the 1980s reported a "paradoxical" lower mortality in patients with lower initial Left Ventricular EF (LVEF) less than 40% and lower cardiac index (CI) \[[@CR9]\]. While recent echocardiographic outcome prediction studies support these findings of LVEF \[[@CR10], [@CR11]•, [@CR12]\], the strain of the myocardium (measured by echocardiographic speckle) was found to be a significant predictor of higher mortality in SICM \[[@CR12]•\]. Additionally, isolated RV dysfunction in sepsis was associated with worse 1-year survival \[[@CR13]\]. A recent database study suggested that among patients with sepsis, echocardiographic assessment of the myocardium influenced hemodynamic management liberated patients from vasopressors earlier and decreased 28-day mortality \[[@CR14]•\]. In summary, LVEF is a poor diagnostic tool, and better measures, such as strain, do suggest that SICM portends a poorer prognosis and proper diagnosis will effect management to improve mortality.

Pathogenesis and Pathophysiology {#Sec5}
================================

A key early trial showed that infusion of LPS in human volunteers resulted in significant myocardial depression and left ventricular dilation within 5 h \[[@CR15]\]. While it was initially thought that SICM was pathologically akin to coronary artery disease, a landmark study showed that the gross coronary perfusion is actually increased in patients with established septic shock \[[@CR16]\]. Since these trials, many myocardial depressant factors have been identified including cytokines, components of the complement cascade, pathogen-associated molecular patterns, endogenous damage-associated molecular patterns, oxidative stress, altered nitric oxide metabolism, mitochondrial dysfunction, abnormal calcium movement within cells, myocyte apoptosis, and autonomic dysregulation \[[@CR17], [@CR18]•\]. Furthermore, the endothelial glycocalyx \[[@CR19]\] is shed in sepsis causing vascular leak, coagulation, and inflammation and is associated with adverse outcomes \[[@CR20]\]. Once disrupted, the endothelium can cause heterogeneous microvascular flow and myocardial edema \[[@CR21]\] which is an underexplored mechanism of SICM. A very recent study \[[@CR21]\] used cardiac magnetic resonance imaging and histology to show that myocardial edema may in part explain the rise of cardiac troponin seen in SICM.

Diagnosis {#Sec6}
=========

Given that there is no definitive agreed upon definition or criteria, the diagnosis of SICM can be difficult. Moreover, it can be challenging to distinguish between cardiovascular system failure (i.e., distributive shock) and cardiac failure (i.e., SICM), and the two often coincide.

Clinical features that suggest the diagnosis include a prior history of heart failure, a "septic, cool extremities phenotype" on clinical exam, hemodynamic instability despite vasopressor therapy, failure to respond to a preload challenge, cardiac dysrhythmias, abnormal echocardiogram, low mixed venous oxygen saturation, and elevated cardiac troponins \[[@CR9], [@CR22], [@CR23]\]. Herein we discuss diagnosis based on electrocardiogram, biomarkers, echocardiogram, and both invasive and non-invasive direct measures of cardiac output.

Electrocardiogram {#Sec7}
-----------------

There are no diagnostic electrocardiographic (ECG) findings of SICM. The most common rhythms include sinus tachycardia and atrial fibrillation (AF). A 2019 meta-analysis concluded that new onset atrial fibrillation occurs in patients without traditional risk factors for the development of AF suggestive that sepsis-induced cardiac changes lead to AF \[[@CR24]\]. While the correlative relationship suggested by these studies links AF with SICM via a similar pathophysiology, it does not lend itself to using AF as a diagnostic or prognostic tool. It is also worth noting that approximately 2% of patients with fever have a fever-induced, type I Brugada pattern in the ECG, \[[@CR25]\] a finding which may be confused with ST elevation due to myocardial ischemia. This is 20 times more common among febrile patients, compared with non-febrile patients \[[@CR25]\]. While not diagnostic for SICM, any abnormal electrocardiograph, especially a change from the baseline, should prompt further cardiac evaluation.

Biomarkers {#Sec8}
----------

### Troponin (cTn) {#FPar1}

In septic patients, elevated cTn is correlated with a greater degree of left ventricular dysfunction, illness severity, and mortality \[[@CR26]--[@CR29]\]. In a meta-analysis of over 1200 patients with sepsis, 61% of subjects with elevated cTn had a twofold increased risk of death compared with patients with undetectable cTn. Multivariate analysis confirmed that increased serum cTn was an independent risk factor for mortality \[[@CR29]\]. Robust evidence linking cTn to prognosis and mortality has led some authors to recommend the use of cTn to risk stratify patients upon admission to the ICU \[[@CR29], [@CR30]\].

### Brain Natriuretic Peptide (BNP) {#FPar2}

Natriuretic peptides also have prognostic value in sepsis \[[@CR11]•, [@CR31]\]. A multicenter, randomized clinical trial of approximately 1000 patients with sepsis and septic shock showed that N-terminal pro-B-type BNP (NT-proBNP) and cTn were elevated in 97.4% and 84.5% of patients, respectively. The degree of biomarker elevation was highly correlated with the development of septic shock and mortality, but NT-proBNP predicted mortality in the ICU and at 90 days better than cTn \[[@CR17]\]. Elevation of natriuretic peptides is so ubiquitous in sepsis that some investigators argue that any association with increased mortality is weakened when illness severity is considered \[[@CR10]\].

Less studied molecules also implicated in septic-induced cardiac dysfunction include histones and heart fatty acid-binding proteins (hFABP). A study of 65 patients with sepsis in the ICU demonstrated that in patients without pre-existing cardiovascular disease, a high histone level showed a significant association with new-onset left ventricular dysfunction \[[@CR32]\]. Another study of 93 patients with sepsis showed that patients with increased serum concentrations of hFABP had higher rates of cardiac dysfunction and were more likely to die within 28 days \[[@CR33]\].

Overall, while elevated cardiac biomarkers are clear indicators of illness severity and prognosis in patients with sepsis, none of these biomarkers are specific to the diagnosis of SICM.

Echocardiography {#Sec9}
----------------

Echocardiography is the cornerstone for the diagnosis of septic cardiomyopathy. There is consensus and expert opinion that every hemodynamically unstable patient should receive critical care echocardiography (CCE) \[[@CR34]•, [@CR35]\]. These findings are summarized in T[able 1](#Tab1){ref-type="table"} and described in more detail below.Table 1Echocardiographic findings in sepsis-induced cardiomyopathyParameterModalityStrengthsWeaknessesLVEFTwo-dimensional echocardiography- Semi-quantitative ("eye-ball")- QuantitativeEasy to obtain (including point of care) and most clinicians are comfortable interpreting the informationLacks sensitivity and specificity. May be "pseudo-normalized" with low afterload. Unclear prognostic role (low LVEF "paradox")SV + COSpectral DopplerCan be used to evaluate fluid responsiveness. May be prognostic. Relatively easy to obtain (point of care)Lacks sensitivity and specificity. Alterations in preload, afterload, and contractility will cause variations which can make consistent interpretation difficultRV dysfunctionTwo-dimensional, spectral Doppler, tissue DopplerPrognostic if present. TDI provides higher quality informationLacks sensitivity and specificity. RV can be difficult to visualize. More advanced imaging techniques require formal echocardiographyDiastolic dysfunctionTwo-dimensional, spectral Doppler, or tissue DopplerMore prognostic than LVEF alone. Basic information relatively easy to obtain, but TDI provides higher quality informationLacks sensitivity and specificity. More advanced imaging techniques require formal echocardiographyGlobal longitudinal strain (LV + RV)Speckle trackingHighly prognostic. Very sensitive assessment of LV, RV, and diastolic dysfunction. Less inter-observer variation. Not dependent on physiology loading parametersRequires special software and equipment. Requires high imaging quality (difficult in critically-ill patients). Lack of consensus on cut-off valuesLVEF, left ventricle ejection fraction; SV, stroke volume; CO, cardiac output; RV, right ventricle; TDI, tissue Doppler imaging; LV, left ventricle

### LVEF {#FPar3}

It was initially thought that diagnosis could be made based solely by a depressed LVEF \[[@CR9]\]. A major problem with the LVEF is that reduced afterload from the distributive shock may pseudo-normalize a depressed EF (coupling between contractility and afterload) \[[@CR36], [@CR37]\]. This likely leads to underdiagnosis of SICM when LVEF is used alone. We think that this explains the "paradox" of improved survival identified by Parker et al. \[[@CR9]\] as a patient with profound shock (vasodilation) with a "normal EF" may do worse than one with less shock and a "low EF" \[[@CR36], [@CR37]\]. Therefore, LVEF in critically ill patients should be reported with the amount of inotropic and vasopressor support and the degree of shock.

### Stroke Volume (SV) and Cardiac Index (CI) {#FPar4}

Both SV and CI can be calculated using left ventricular outflow tract (LVOT) diameter and the velocity time integral (VTI), but the measurement of these indices is hard to interpret in SICM because of the profound variations in preload, afterload, and contractility intrinsic to septic shock. Studies have, however, found that sepsis survivors have higher VTI and CI upon ED presentation \[[@CR38]\].

### Right Ventricle (RV) Systolic Dysfunction {#FPar5}

Approximately two-thirds of patients with sepsis and septic shock have RV dysfunction and, as stated above, it is an independent risk factor of 1-year survival \[[@CR13]\]. Measurements of RV function include the RV end-diastolic area in comparison to the LV, the RV fractional area change with tricuspid annular plane systolic excursion and tricuspid annulus tissue Doppler imaging (TDI), and the RV free wall TDI have been used. A study suggested that the RV wall strain was the most important predictor of mortality in patient with SICM \[[@CR11]•\]. All patients with a RV global longitudinal strain (GLS) less negative than − 13% died within 20 days \[[@CR11]•\].

### Diastolic Dysfunction {#FPar6}

LV diastolic function is very common in septic shock. The septal relaxation in TDI (e'-wave, abnormal \< 8 cm/s) was a very strong predictor of mortality in septic shock patient, after adjusting for severity of illness, comorbidities, and other echocardiographic indices \[[@CR39]\]. Another study measuring the peak early diastolic transmitral velocity during the passive filling of the heart (E)/peak early diastolic mitral annular TDI velocity (e') showed significant and independent prediction of mortality. The E/e' prime also allows approximation of the wedge pressure via the rough formula E/e' + 4.6 \[[@CR40]\]. A recent meta-analysis confirmed these findings showing strong associations of both lower e' and higher E/e' in predicting mortality in critically ill patients with sepsis \[[@CR41]\]. It is uncertain however, if specific reversible lusitropic interventions will improve outcomes \[[@CR42]\].

### Speckle Tracking {#FPar7}

Newer echocardiographic modalities have revealed further insight in SICM. Speckle tracking was developed in 2014 and uses advanced, non-Doppler algorithms to track myocardial segments, by the displacement of acoustic "speckles." A small pilot trial showed that myocardial impairment in sepsis can be detected by the global longitudinal strain (GLS), in other words, the displacement of myocardial speckles in the longitudinal axis, denoting the base-to-apex contractility of the heart. Normal values are − 17 to − 23% (more negative is better). In patients with septic shock, GLS proved to be the most sensitive measurement of SICM with an average − 14% among patients with septic shock \[[@CR43]\]. Interestingly the LVEF of those patients was normal \[[@CR43]\]. A key benefit of the speckle tracking is that it is not as susceptible to afterload reduction pseudo-normalization that plagues the LVEF. Several trials have confirmed the benefit of the LV \[[@CR11]•, [@CR12]•, [@CR43]--[@CR47]\], and the RV GLS \[[@CR11]•\] in diagnosing SICM.

### Gross Visual Examination {#FPar8}

In addition to "eyeballing" the LV and RV function and size, echocardiography allows evaluation of the large vessels and the pericardium. This is also important in ruling out other diagnoses in the differential of SICM such as sepsis-related Takotsubo cardiomyopathy, pericardial effusion, dissection, acute coronary syndromes, early dynamic intraventricular obstruction (IVO) syndromes such as systolic anterior motion of the mitral valve (SAM), and mid-cavitary obstruction syndromes \[[@CR48]\].

### Situational Awareness {#FPar9}

A final and key note for the echocardiographic evaluation of patients with possible septic cardiomyopathy is situational awareness. It is easy for a clinician to get distracted, lose track of time, and engage in prolonged echocardiographic evaluations of patients with suspected septic cardiomyopathy. This pitfall can divert the attention from lifesaving interventions such as ensuring timely and correct antimicrobial administration and securing the patient's airway. A recent study has shown that the point-of-care ultrasound and echocardiography were associated with delays and increased mortality in critically ill patients \[[@CR49]\].

Invasive Devices {#Sec10}
----------------

While it can be used to directly measure CO and other hemodynamic parameters, the pulmonary artery (PA) catheter has fallen out of favor because its use does not provide a mortality benefit \[[@CR50]\]. In addition, a "normal" CO does not rule out SICM since a low SVR may falsely elevate the measured CO, and CO does not necessarily reflect intrinsic cardiomyocyte function/contractility. To overcome the former barrier, Werdan et al. developed an "afterload-related cardiac performance" (ACP) calculation to integrate information from both SVR and CO \[[@CR51]\]. The derived calculation is ACP (%) = CO ~measured~/CO ~predicted~ × 100% with \> 80% considered normal. CO ~predicted~ was derived for this calculation with a nonlinear regression model obtained from a cohort of 524 patients. They reported that this measure has both diagnostic and prognostic utility in their small, single-center study \[[@CR51]\]. In 2013, they expanded upon these findings with a larger study; however, all data was collected at the same center, and further studies are needed before many clinicians would consider resurrecting the routine use of PA catheters for this purpose \[[@CR52]\].

Non-Invasive Devices {#Sec11}
--------------------

Non-invasive measures (such as pulse contour analysis, pulse pressure variation, and stroke volume variation) have an evidence-based role in evaluating fluid responsiveness in patients with septic shock, but there are certainly limitations to their use. We could not find any articles validating their use in the diagnosis or management of SICM. While they are promising devices, further studies are needed to validate their use in the setting of SICM prior to standardized use.

Management {#Sec12}
==========

There are no studies outlining treatment goals for SICM other than Dr. Rivers' initial study on early goal-directed therapy (EGDT) which is now the subject of debate \[[@CR53]\]. Although the recent ProCESS, ARISE, and ProMISe studies showed no outcome differences when EGDT is applied indiscriminately, it is possible that a subset of patients with a diagnosis of SICM may benefit from titrating therapy to mixed venous oxygen saturation and lactate clearance, and future studies would be helpful \[[@CR54]--[@CR56]\]. As summary of current treatment, options are provided in Table [2](#Tab2){ref-type="table"}.Table 2Management of sepsis-induced cardiomyopathyTherapyMechanism of actionProConVasopressorsVasoconstriction by alpha or beta adrenergic, vasopressin, or dopamine receptor stimulationPhysician familiarity. Well studied in septic shock. Alpha-adrenergic, dopamine, and vasopressin activity will help with decreased afterload. Beta and dopamine activity will increase contractilityIncreasing afterload too much may "unmask" cardiac dysfunction (especially with isolated vasoconstrictive drugs phenylephrine and vasopressin). The beta-adrenergic and dopamine activity could increase myocardial demand leading to worsening cardiomyopathy and/or arrhythmiasFluidsIncreasing preload with increase stroke volume based on Frank--Starling relationshipsIncreasing stroke volume will increase cardiac outputCardiomyopathy will shift the Frank--Starling curve and overaggressive fluid management can lead to worsening organ failureDobutamineBeta-adrenergic selective agentPhysician familiarity. Most studied with proven improvement in cardiac parameters (i.e., CO)Increased myocardial demand and vasodilation may worsen hemodynamics. Risk of arrhythmias. May not improve outcomesMilrinonePhosphodiesterase inhibitor increases cAMPIncreased contractility without adrenergic activity. No trials for SICMVasodilation. Limited by renal dysfunction. Risk of arrhythmiasLevosimendanCalcium sensitizer and potassium channel activatorHelps with calcium signaling to increase contractility in an adrenergic-dependent manner so less oxygen demandVasodilation. Mixed information about mortality with the largest trial suggesting increased mortalityBeta blockersBeta-adrenergic blockadeMay help decrease the pathogenesis of SICM by decrease myocardial demandNegative inotropic effect. Patients with cardiac dysfunction were excluded from the largest trialsIvabradineSelective inhibitor of the I~f~ channelLower myocardial demand without negative inotropic effect found in beta blockersPossible worsened mortality, but data sparse and not specific to SICMMethylene blueNitric oxide metabolismTreats vasoplegia. Improves catecholamine responsiveness. May improve vasopressor requirementNo change in outcomes. Risk of serotonin syndrome. Can cause worsening oxygenation by pulmonary vasoconstriction. Hemolytic anemia in G6PD deficiency. Interference with pulse oximetry. Contraindicated with renal dysfunctionMechanical supportProvide bypass or mechanical assistance of cardiac outputProvides aggressive supportive care until reversibility occursInvasive with relatively high risk of complications. Must choose right deviceCO, cardiac output; cAMP, cyclic adenosine monophosphate; SICM, sepsis-induced cardiomyopathy; G6PD, glucose-6-phosphate dehydrogenase

Vasopressors {#Sec13}
------------

Based on previous studies, the surviving sepsis campaign recommends norepinephrine be used as first line for septic shock with epinephrine or vasopressin added as a second agent \[[@CR63]\]. Norepinephrine has stronger alpha-adrenergic profile compared with beta-1 which results in increased afterload more than increased myocardial function. While this is essential for the treatment of distributive shock, increasing afterload will drop cardiac output and could result in the "unmasking" of cardiac dysfunction. While epinephrine and dopamine have more favorable alpha to beta-1 adrenergic activity profiles, they are consequently associated with more arrhythmias. In the case of dopamine, risk of arrhythmias and potential increased mortality has led to the recommendation against its use for septic shock. It is worth noting that these guidelines did not identify patients with SICM and are guides for the management of septic shock in general. There are no trials that we could find to validate adopting these guidelines to patients with SICM \[[@CR57]\]. There was one study which showed that phenylephrine improved cardiac function in septic rats and inhibited myocyte apoptosis suggesting that this could be used specifically for SICM, but there are no corresponding human studies \[[@CR58]\]. The risk of isolated alpha-vasoconstriction without any beta-1 could cause increased afterload and decreased CO potentially worsening hemodynamics so further studies are needed.

Fluid Management {#Sec14}
----------------

It is being increasingly recognized that over resuscitation can have detrimental effects. Studies, such as the SOAP trial, show that a positive fluid balance is a poor prognostic factor \[[@CR59]\]. This effect is likely to be more dramatic in patients with septic cardiomyopathy because of abnormal Frank--Starling relationships. It is necessary to be judicious with fluid management after the initial resuscitation phase by using dynamic measures of fluid responsiveness such as pulse pressure variation, inferior vena cava collapse, passive straight leg raise, and end-expiratory occlusion. While each of these measures has strengths and weakness, the overarching goal of these measures is to account for differences in cardiac function as it relates to fluid responsiveness in a dynamic manner rather than traditional static measures (i.e., CVP, PCWP). Currently the PETAL Network is recruiting for the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) to further evaluate this topic. Patients with known contraindications to liberal fluids are excluded from the trial and this may make generalizability to patients with SICM difficult.

Inotropes {#Sec15}
---------

The Surviving Sepsis Guidelines currently support the use of dobutamine to augment vasopressor therapy in the appropriate clinical scenarios, but the evidence for its use is sparse. There certainly are potential downfalls to the use of inotropic agents in septic cardiomyopathy, such as increase myocardial demand and vasodilation. Because of their mechanism of actions, milrinone and levosimendan have the theoretical advantage of acting outside of the adrenergic pathway which is known to be dysfunction in SICM.

### Dobutamine {#FPar10}

A meta-regression analysis by Naedeem et al. did showed improved cardiovascular parameters in patients with septic shock treated with dobutamine which justifies the efficacy of dobutamine but did not investigate outcomes \[[@CR60]\]. Hernandez and colleagues, however, performed a randomized controlled trial on the microcirculatory perfusion in patients with septic shock with low cardiac output, and despite an increase in CI, those parameters did not improve with dobutamine \[[@CR61]\]. This suggests that although CO improves with dobutamine, it may not overcome the end-organ damage intrinsic in septic states. It seems intuitive that cardiac output needs to be supraphysiologic in the septic state, but Gattinoni et al. found that targeting supranormal values of cardiac index did not improve morbidity or mortality \[[@CR62], [@CR63]\].

Given the potential pitfalls of inotropic therapy, there are some studies to corroborate the downsides. Hayes et al. found that using dobutamine to augment cardiac index and systemic oxygen delivery worsened in-hospital mortality. In this study, though, all patients were treated with dopamine, and we can surmise from the dopamine data that the combination of dopamine and dobutamine is high risk for arrhythmias \[[@CR64]\]. Further, a retrospective study by Wilkman et al. showed an increased 90-day mortality in patients with septic shock treated with inotropes \[[@CR65]\]. Only a correlation, however, can be surmised from that study which may be representative of worse prognosis with septic cardiomyopathy. This seems to be supported by trials by Rhodes and Kumar in which they showed failure of cardiac output to increase with dobutamine portends a poorer prognosis \[[@CR66], [@CR67]\]. Two other interesting studies on potential pitfalls of dobutamine are done by Lyte suggesting that dobutamine facilitates biofilm formation on indwelling catheters in vitro and one by Hartemink in which dobutamine is associated with increased circulating TNF-alpha levels \[[@CR68], [@CR69]\].

### Milrinone {#FPar11}

There are even fewer studies on the use of milrinone in sepsis and none in septic cardiomyopathy. In a pediatric trial, Barton showed improved cardiovascular function with milrinone in patients with "nonhyperdynamic" septic shock without adverse outcomes (did not include patients with Cr \> 2.0) \[[@CR70]\]. A prospective, non-randomized trial in septic shock found that the combination of milrinone and PO metoprolol augmented cardiac index with lower heart rate and higher stroke volume index potentially mitigating the arrhythmogenic side effects of inotropes \[[@CR71]\]. One major factor to consider is renal impairment which is present in many patients with sepsis and may limit widespread use.

### Levosimendan {#FPar12}

Levosimendan is an attractive therapy for septic cardiomyopathy because it targets cardiomyocyte calcium signaling which is known to be pathologic in septic cardiomyopathy. Moreover, it acts in a catecholamine-independent manner to minimize effects on oxygen demand, arrhythmias, and catecholamine resistance from sepsis. Morelli et al. performed a randomized, prospective trial published in 2005 which showed levosimendan improved hemodynamics (LVEF + CI) in patients not responsive to dobutamine at 5 microg/kg/min because of adrenergic hyporesponsiveness. They also showed that levosimendan increased gastric mucosal flow, creatinine clearance, urine output, and lactate clearance compared with dobutamine \[[@CR72]\]. A meta-analysis (of 7 trials) by Zangrillo published in 2015 showed that levosimendan had a mortality benefit when compared to dobutamine \[[@CR73]\]. The next major trial to come out was the LeoPARDS trial in 2016. This double-blind RCT compared levosimendan to placebo plus standard of care for sepsis and found no difference in SOFA scores or mortality but a trend toward worse mortality with levosimendan. In addition, the levosimendan group was more likely to have SVT, required higher vasopressor doses, and was less likely to be weaned from ventilator. Of note, in the placebo arm, less than 10% of patients received inotropic support, which does bring into question the prevalence of SICM in the study population \[[@CR74]•\]. Overall, the data for levosimendan is mixed, and the LeoPARDS trial should give practitioners pause before adopting its use broadly.

Rate Control {#Sec16}
------------

### Beta Blockers {#FPar13}

Beta blockers have been shown to be beneficial in many cardiovascular diseases, but their use in sepsis is controversial. It would seem that any negative inotropic effects would be detrimental to a patient who is relying on a hyperdynamic state, but this increased adrenergic state seems to play a role in the pathogenesis of septic cardiomyopathy. For this reason, the use of selective beta-blockers may help to decrease myocardial oxygen demand, increase diastolic filling, and ultimately improve septic cardiomyopathy. Early studies showed that esmolol did not change lactate and reduced TNF-alpha levels, and that beta-1 selective agents may have anti-inflammatory effects \[[@CR75], [@CR76]\]. An observational study of 9465 cases of sepsis found that patients prescribed with beta-blockers prior to admission had a significantly lower mortality (17.7% vs 22.1%) \[[@CR77]\]. This sparked interest in prospective studies, the largest of which was performed by Morelli; they performed a non-blinded RCT which showed that the use of esmolol targeting a heart rate of 80--94 increased stroke volume and reduced vasopressor requirement. They also found an improved 28-day survival, but they were not powered for this outcome, and mortality in the placebo group was 80% which is much higher than expected \[[@CR78]•\]. Moreover, patients with cardiac dysfunction were excluded from this trial, so its application to patients with SICM is unknown.

### Ivabradine {#FPar14}

Ivabradine is an attractive rate control agent because it provides heart rate lowering effects without the negative inotropy associated with beta blockers. An observational study of 3 patients found that its use improved heart rate, stroke volume index, end-diastolic volume index, and SvO2 while decreasing lactate and norepinephrine dose \[[@CR79]\]. This should be taken with a grain of salt as a larger trial demonstrated a trend toward worsened mortality in ivabradine group, but this did not reach statistical significance \[[@CR80]•\]. This larger trial, however, is difficult to interpret in relation to SICM as patients with both cardiac and septic shock were included, and the subgroups were not analyzed separately.

Methylene Blue (MB) {#Sec17}
-------------------

As noted earlier, nitric oxide metabolism plays a role in the development of septic shock when inflammatory substrate activates nitric oxide synthase (NOS) thus increasing NO production. This has a vasodilatory effect as well as impairing the cardiovascular systems response to catecholamines. Methylene blue has routinely been used to treat vasoplegia after cardiovascular surgery because it acts by inhibiting guanylate cyclase and NOS to counteract this mechanism. A 2014 review by Lo et al. found 16 articles on the topic of MB for the treatment of septic shock including two randomized controlled studies. These studies showed a significant improvement in blood pressure and decreased requirement for vasopressors but no difference in other outcomes \[[@CR81]--[@CR83]\]. There is only one case report describing the successful use of MB specifically for septic cardiomyopathy in a burn patient by Schlesinger in 2016 \[[@CR84]\]. Like all therapies, MB is not without risks; it can contribute to serotonin syndrome, worsening arterial oxygenation (through pulmonary vasoconstriction), infiltration injury, and impaired mesenteric blood flow. Overall, MB is a potential treatment for septic shock, and more evidence is necessary before it can be adopted broadly for the treatment of septic cardiomyopathy.

Mechanical Support {#Sec18}
------------------

Mechanical support is widely used in cardiogenic shock due to congestive heart failure, and its use in septic cardiomyopathy is based upon that experience. There are no randomized controlled trials for intra-aortic balloon pump (IABP), percutaneous ventricular assist devices, or extracorporeal membrane oxygenation (ECMO). There are multiple case reports providing examples of both successful and unsuccessful use of these devices in patients with septic cardiomyopathy. One consideration before deciding on the appropriate support device is the patient-specific hemodynamics such as LV, RV, or Bi-V failure and systolic vs diastolic dysfunction. In their 2015 review, Sato and Nasu provide a summary of the ECMO case reports in which 18/23 patients survived \[[@CR30]\]. Without larger studies, this therapy should only be considered in extreme cases.

Emerging Therapies {#Sec19}
------------------

As our understanding of the pathophysiology of SICM grows, so does the potential for targeted therapy. There are many potential therapies being investigated in the laboratory setting, largely in animal models of septic cardiomyopathy. Potential therapies include statins, dexmedetomidine, hydrocortisone, alpha-2 blockers, yohimbine, Chinese yam, erythropoietin, vitamin c, and sulfur dioxide among others \[[@CR85]--[@CR96]\]. As these treatments transition from the bench to the bedside, potential therapeutic efficacy will need to be evaluated. It is important to remember from historical studies in sepsis in the 1990's that translation of animal models to human studies has its limitations \[[@CR85]\].

Conclusion {#Sec20}
==========

SICM is currently an under recognized entity that has significant prognostic and mortality implications for our patients. A summary of the basic pathophysiology, work-up, and management of SICM is provided in Fig. [2](#Fig2){ref-type="fig"}. Clinicals should consider the diagnosis in patients with sepsis-associated organ dysfunction and particularly septic shock requiring vasopressor therapy. Biomarkers can provide prognostic information and put SICM on the clinician's radar, but their diagnostic utility is limited. Echocardiography is currently the gold standard of diagnosis, and evaluation of global longitudinal strain is more sensitive and specific for SICM than LVEF or other common findings alone. Standard management includes the use of vasopressors, inotropes, and judicious fluid resuscitation, but large studies validating these measures are lacking. Additionally, while there is growing evidence for other therapies for SICM, more data is needed to make any definitive recommendations about adopting them to everyday practice. Finally, a consensus statement on diagnostic criteria is currently lacking and is essential in future studies evaluating treatment.Fig. 2Summary of basic pathophysiology and proposed diagnosis and management of sepsis-induced cardiomyopathy. Risk factors include a history of congestive heart failure. Biomarkers while sensitive, are not specific, but do portent a poorer prognosis. Echocardiography should include global longitudinal strain which is the most sensitive and specific (although there are no agreed upon cutoff values). Judicious fluids should include dynamic measures (such as pulse pressure variation) to judge fluid responsiveness. Norepinephrine is considered the standard vasopressor and dobutamine is considered the standard inotrope. There is limited evidence for other vasopressors or inotropes. Adjuncts can include mechanical support (i.e. ECMO). PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; NO, nitric oxide; TTE, transthoracic echocardiogram; ECMO, extracorporeal membrane oxygenation
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